Conference Details - Abstract
Continuing Education Information
Physicians: Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.This activity is approved for AMA PRA Category 1 Credit™
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.
13th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myelomas
The Fairmont Château Whistler
Whistler, British Columbia, Canada
February 11-15, 2009
Abstract Submission Instructions
The 13th Annual International Congress on Hematologic Malignancies:
Focus on Leukemias, Lymphomas, and Myelomas is accepting abstracts for consideration for poster presentations.
Deadline for submission is January 12, 2009.
Abstracts must be e-mailed as a Word document to info@cancerlearning.com.
$100.00 Discounted Registration Fee for Accepted Poster Submissions
Instructions for submitting an abstract:
- Submissions are accepted as a Word document via e-mail only.
- Include the key contact information for the abstract in the e-mail:
- Name, credentials
- Title
- Organization
- Specialty
- Address
- City, state/province, postal code, country
- Phone, fax, e-mail address
- Underline the presenter of the paper, and spell out the complete name of each author.
- List city, state, country, and institution of origin.
One week after the close of submissions, you will receive notification of the acceptance or nonacceptance of the abstract.
Upon acceptance, you will be provided specific information on the preparation of the abstract as a poster as well as the date and times of the poster session.
Accepted abstracts will be published in the program material and might be selected for publication in the Cancer Information Group journals Clinical Leukemia or Clinical Lymphoma & Myeloma.
Educational Grants
An educational grant for this activity was provided by:
- Genentech BioOncology/
Biogen Idec - Cephalon Oncology
- GlaxoSmithKline
- Novartis Oncology
- Bristol-Myers Squibb
- Eisai, Inc.
- Allos Therapeutics, Inc.
- Merck Oncology
- Biogen Idec
- Celgene Corporation